Anti-inflammatory H1 Antihistamines Allergic Rhinitis

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of the treatment of persistent allergic rhinitis is to improve symptoms and patients' quality of life and prevent the development of asthma. Therapeutic strategies also target a reduction of pro-inflammatory mediators released from activated cells, including mast cells and epithelial cells. The presence of allergic inflammation in nasal mucosa may increase the risk of asthma occurrence, especially in patients with persistent allergic rhinitis. H1 antihistamines are widely recommended in all types of allergic rhinitis, regardless of symptom severity or persistence. They control all of the symptoms, but to a lesser extent nasal congestion. New generation agents, such as levocetirizine and desloratadine, possess anti-inflammatory properties, reducing allergic inflammation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Iuliu Hatieganu University of Medicine and Pharmacy
• Treatments: Anti-Inflammatory Agents; Cetirizine; Desloratadine; Histamine Antagonists; Histamine H1 Antagonists; Levocetirizine

Criteria

Inclusion Criteria:

• persistent allergic rhinitis

Exclusion Criteria:

• the presence of asthma or nasal polyps,

• acute and chronic upper respiratory infections,

• administration of intranasal or systemic corticosteroids or H1 antihistamines in the past 30 days.